UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
_____________

FORM 8-K
_____________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of report (Date of earliest event reported):  April 14, 2009


Keryx Biopharmaceuticals, Inc.
 (Exact Name of Registrant as Specified in Charter)


Delaware
(State or Other Jurisdiction
of Incorporation)
000-30929
 (Commission File Number)
 
13-4087132
 (IRS Employer Identification No.)


750 Lexington Avenue
New York, New York 10022
 (Address of Principal Executive Offices)

(212) 531-5965
 (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£  
Written communications pursuant to Rule 425 under the Securities Act.
£  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.


Item 4.01.  Changes in Registrant’s Certifying Accountant.

(b) On April 14, 2009, the Audit Committee of the Board of Directors of Keryx Biopharmaceuticals, Inc. (“the Company”) engaged UHY LLP (“UHY”) as its new independent registered public accounting firm.

During the fiscal years ended December 31, 2008 and 2007 and through April 14, 2009, the Company did not consult with UHY regarding any of the matters or events set forth in Item 304(a)(2)(i) and (ii) of Regulation S-K.
 
 
SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
Keryx Biopharmaceuticals, Inc.
(Registrant)
  
       
       
       
Date:  April 17, 2009   
By:
/s/ James F. Oliviero
  
   
James F. Oliviero
  
   
Vice President, Finance